TABLE 2.
MIC values obtained for clinical isolates from Poland (n = 62) with Etest methodb
| Type (clinical isolates; n = 62) | NTM disease | RIF |
CLR |
INH |
EMB |
STR |
AMK |
SXTa |
KAN |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | R | M | MIC50/90 | ||
| I (n = 39) | Yes | 0.002–0.047 | 0.008 | 0.008/0.023 | <0.016–>256 | 0.047 | 0.047/0.47 | <0.016–>256 | >256 | >256/>256 | 0.125–12 | 0.5 | 0.5/1.5 | 0.38–6 | 1.5 | 1.5/4 | 0.25–12 | 1.5 | 1.5/4 | >32 | >32 | >32 | 0.125–24 | 2 | 2/12 |
| I (n = 22) | No | <0.002–0.023 | 0.01 | 0.012/0.016 | <0.016–0.25 | 0.064 | 0.064/0.125 | <0.016–>256 | >256 | >256/>256 | 0.19–8 | 0.69 | 0.64/1.5 | 0.125–>1,024 | 2.5 | 2/4 | 0.25–6 | 1.75 | 1.5/6 | >32 | >32 | >32 | 0.38–24 | 2.5 | 1/12 |
| II (n = 1) | No | 0.047 | 0.047 | 0.047 | 0.064 | 0.064 | 0.064 | >256 | >256 | >256 | 0.38 | 0.38 | 0.38 | 2 | 2 | 2 | 0.75 | 0.75 | 0.75 | >32 | >32 | >32 | 2 | 2 | 2 |
| Total | <0.002–0.047 | 0.008 | 0.008/0.023 | <0.016–>256 | 0.047 | 0.047/0.125 | <0.016–>256 | >256 | >256/>256 | 0.125–12 | 0.5 | 0.5/1.5 | 0.125–>1,024 | 1.5 | 1.5/4 | 0.25–12 | 1.5 | 1.5/4 | >32 | >32 | >32 | 0.125–24 | 2 | 2/12 | |
a
For SXT (ratio of 1:19 for trimethoprim to sulfamethoxazole), the concentration of trimethoprim is indicated.
b
R, MIC ranges; M, median MIC.